Streetbeat News

Stock Prices

ISRG

Deep-pocketed investors have shown a bearish sentiment towards Intuitive Surgical (NASDAQ:ISRG), as revealed by Benzinga's tracking of public options records. The analysis of options activity indicates a divided sentiment among investors, with a significant lean towards bearishness. The trading activity suggests a price range target of $310.0 to $450.0 for ISRG over the next three months. Additionally, professional analysts have provided an average price target of $431.4 for ISRG, with ratings ranging from Overweight to Buy.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 6:30 pm

FN

Over the past decade, Fabrinet (NYSE:FN) has significantly outperformed the market, yielding an average annual return of 26.69%. A $1000 investment in FN 10 years ago would now be worth $10,761.58. Fabrinet's market capitalization stands at $7.12 billion.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 6:30 pm

MA

Over the past 5 years, Mastercard (NYSE:MA) has outperformed the market with an annualized return of 15.97%, growing a $1000 investment to $2,103.62. The company's market capitalization stands at $432.56 billion.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 6:30 pm

AGRX

Agile Therapeutics Inc (NASDAQ:AGRX) shares surged during Thursday's trading session, with a volume of 9.91 million compared to its average of 78.141K. The company announced the immediate exercise of warrants to purchase up to 3.89 million shares at a reduced price of $1.25 per share, expecting gross proceeds of approximately $4.8 million. Additionally, new unregistered warrants to purchase up to 7,785,144 shares at $1.00 per share will be issued. AGRX shares rose 2.80% to $1.02, with a premarket peak at $2.68.

Portfolio Pulse from Vandana Singh

February 22, 2024 | 6:26 pm

NVDA

Bernstein analyst Stacy Rasgon maintains an Outperform rating on NVIDIA (NASDAQ:NVDA) and raises the price target from $700 to $1000.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 6:25 pm

GRAM

Glass House Brands CEO Kyle expressed optimism about California's future in the cannabis industry, highlighting the state's potential once regulatory constraints are removed. He noted the current challenges faced by retailers and brands in the cannabis market, advising investors to be cautious. Kyle also suggested that businesses relying on indoor cultivation and a large number of stores might need to reconsider their models to stay competitive.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 6:19 pm

NVDA

TSLA

Jim Cramer praised Nvidia's CEO, Jensen Huang, as a greater visionary than Tesla's Elon Musk, following Nvidia's strong Q4 earnings. Nvidia's success, driven by demand for its AI chips, contrasts with Tesla's recent underperformance. Cramer highlighted Nvidia's potential for continued growth and its impact on the tech industry.

Portfolio Pulse from Adam Eckert

February 22, 2024 | 6:17 pm

DASH

Financial giants are showing a bullish stance on DoorDash (NASDAQ:DASH) through options trading, with 65% of trades being bullish. The trading activity suggests a target price range of $100 to $165 for DASH in the next three months. DoorDash's current stock price is up 6.59% at $122.25, with analysts giving mixed ratings but an average target price of $134.8. The company has seen significant growth, with a 25% increase in gross order volume and a 31% increase in revenue year over year.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 6:16 pm

CRSP

Smart money investors have shown a bearish stance on CRISPR Therapeutics (NASDAQ:CRSP), with unusual options trading activity observed. Benzinga's options scanner revealed 26 significant trades, with a sentiment split of 38% bullish and 61% bearish. The trades suggest a price target range of $50.0 to $110.0 for CRSP over the next three months. The company, a leader in gene editing technology, is currently trading at $82.0, with a slight decrease of -0.5%. Its most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 6:15 pm

NVDA

HSBC analyst Frank Lee has maintained a Buy rating on NVIDIA (NASDAQ:NVDA) and increased the price target from $835 to $880, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 6:11 pm